Sharp Therapeutics Corp.
1.37
CAD
0.00
(0.00%)
ISIN
CA8200092077
CUSIP
820009207
Return %
Stock
S&P 500
1Y
-54.33
14.20
3Y
24.55
81.12
5Y
- -
68.34
Capital Structure
USD
•
in mil. unless spec.Working Capital
USD
•
in mil. unless spec.Growth Rates
USD
•
in mil. unless spec.Quarterly Revenue
USD
•
in mil. unless spec.Quarterly Earnings Per Share
USD
•
in mil. unless spec.Quarterly Dividends Per Share
USD
•
in mil. unless spec.Company Description
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Pittsburgh United States
- Website
- sharptx.com
- Similar Companies
- Business
- Sharp Therapeutics Corp. is a preclinical-stage biotechnology company focused on the discovery and development of orally bioavailable, small-molecule therapeutics designed to restore mutant protein function in rare genetic diseases and neurodegenerative disorders. The company operates in the biotechnology and biopharmaceuticals sector, utilizing its proprietary discovery platform to target underlying cellular defects in inherited conditions. Sharp Therapeutics Corp. offers and advances a portfolio of proprietary technologies and pipeline programs comprising the Disco Drug Discovery Platform, an integrated system designed to identify small molecules that allosterically modulate and stabilize target proteins; CoreX, a proprietary suite of biological assay technologies that recreate functional genetic disease states in cellular models; AlloChem, a chemically diverse compound library optimized for allosteric protein binding; Mine, a cloud-distributed machine learning and data analytics engine that processes high-throughput screening data; the GBA1 Program, a preclinical therapeutic candidate targeting glucocerebrosidase mutations associated with Gaucher disease and Parkinson's disease; the NPC Program, an investigative asset designed for the treatment of Niemann-Pick disease Type C; and the Progranulin Program, a drug candidate targeting progranulin deficiencies in familial frontotemporal dementia. Originally founded in 2010 as Sharp Edge Labs, Inc., a spinout from Carnegie Mellon University, the company is headquartered in Pittsburgh, Pennsylvania, United States. In recent corporate developments, the company completed a qualifying transaction and reverse takeover of EVP Capital Inc. in December 2024, subsequently adopting the name Sharp Therapeutics Corp. and listing its common shares on the TSX Venture Exchange under the ticker symbol SHRX and on the OTCQB Venture Market under the ticker symbol SHRXF. In mid-2026, the company closed a non-brokered private placement financing raising gross proceeds of approximately C$1.365 million to support general working capital and advance its lead preclinical pipeline programs toward planned Phase I clinical trials in 2027.